SCHEMBL8733206

SCHEMBL8733206

Cc1ccc2[nH]c(NN)nc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.48
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
ADORA2A P29274 1/20 0.46
GAA P10253 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NPC1 O15118 6/20 0.43
RAB9A P51151 6/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
GFER P55789 1/20 0.43
HIF1A Q16665 1/20 0.43
PKM P14618 2/20 0.43
POLB P06746 2/20 0.41
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15246752 0.86 MAPT (0.46) MAPTKMT2AMEN1CYP1A2CYP2C9
SCHEMBL8733213 0.86 ADORA2A (0.62) MAPTKMT2AMEN1CYP1A2CYP2C9
SCHEMBL15942807 0.84 ADORA2A (0.47) MAPTKMT2AMEN1CYP1A2CYP2C9
SCHEMBL11784559 0.81 CSNK1D (0.46) MAPTKMT2AMEN1CYP1A2CYP2C9
SCHEMBL2632885 0.79 RAB9A (0.51) MAPTKMT2AMEN1CYP1A2CYP2C9
SCHEMBL12724899 0.79 ADORA2A (0.44) MAPTKMT2AMEN1CYP1A2CYP2C9
SCHEMBL4686558 0.79 MEN1 (0.52) MAPTKMT2AMEN1CYP1A2CYP2C9
SCHEMBL16342365 0.79 RAB9A (0.45) MAPTKMT2AMEN1CYP1A2CYP2C9
SCHEMBL16342360 0.78 SCN10A (0.45) GAANPC1CSNK1A1CSNK1DGSK3B
SCHEMBL9719979 0.78 NPC1 (0.54) MAPTKMT2AMEN1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4702017-A1 SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd (KY) 2026-03-04 EP disclosed
US-9212169-B2 Benzimidazole derivative and use thereof HYOGO COLLEGE OF MEDICINE (JP) 2015-12-15 US disclosed
US-9212169-B2 Benzimidazole derivative and use thereof HYOGO COLLEGE OF MEDICINE (JP) 2015-12-15 US disclosed
US-9212169-B2 Benzimidazole derivative and use thereof HYOGO COLLEGE OF MEDICINE (JP) 2015-12-15 US disclosed
US-20150011600-A1 NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREOF KAGOSHIMA UNIVERSITY (JP) 2015-01-08 US disclosed
US-20150011600-A1 NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREOF KAGOSHIMA UNIVERSITY (JP) 2015-01-08 US disclosed
US-20150011600-A1 NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREOF KAGOSHIMA UNIVERSITY (JP) 2015-01-08 US disclosed
WO-2013129674-A1 NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREOF 学校法人兵庫医科大学 (JP) 2013-09-06 WO disclosed
WO-1998043649-A2 AGE PRODUCTION INHIBITORY COMPOSITION COMPRISING A MAILLARD REACTION INHIBITOR AND VITAMIN B¿6? OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1998-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150011600-A1 NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREOF HDAC1, HDAC11, HDAC6 MAPT 1534/4885KMT2A 1356/4885MEN1 1799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.